Clinuvel accredits first European EPP expert centres
Filed with ASX · · 2 pages · English
Clinuvel Pharmaceuticals Limited on 6ix
Earlier from Clinuvel Pharmaceuticals
- Clinuvel Placement
- Clinuvel brief on European commercialisation
- US FDA orphan designation received for cutaneous porphyrias
- Update on North American vitiligo program for SCENESSE
- TGA grants Orphan Drug Designation for SCENESSE
Later from Clinuvel Pharmaceuticals
- Clinuvel enters a joint venture with Biotech Lab Singapore
- EMA Oral Explanation Update
- JAMA Dermatology publishes SCENESSE vitiligo study results
- Clinuvel declines unsolicited proposal from Retrophin
- EMA review of SCENESSE extended to mid-2014
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals